Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547987 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Mothaffar Rimawi.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT02547987: Active Phase 2 study of Breast Cancer, sponsored by Mothaffar Rimawi.
NCT02547987 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Mothaffar Rimawi. The registered enrollment target is 25 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02547987, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Mothaffar Rimawi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
Study Locations (3)
Texas
- Lester & Sue Smith Breast Center at Baylor College of Medicine - Houston
- Harris Health System Smith Clinic - Houston
Ohio
- TriHealth Hatton Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02547987
The ClinicalTrials.gov registry entry for NCT02547987 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Mothaffar Rimawi, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT02547987 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT02547987 about?
NCT02547987 is a clinical study titled "Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer". The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
What is the current status of trial NCT02547987?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-11-01. Estimated completion is 2025-09.
What conditions does trial NCT02547987 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02547987?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT02547987?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02547987 being conducted?
This trial has 3 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.